Skip to content
Operation Infinite Justice – Lifestyle
Author:
Krystal Biotech, Inc.
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
July 23, 2026
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
May 18, 2026
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
May 7, 2026
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
May 4, 2026
Krystal Biotech to Present at Upcoming Scientific Conferences
April 30, 2026
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
April 21, 2026